Prone To Death
Statistical analysis
Edi Itelman
14/04/2021
Censor
- patients were censored if “Prone to death” status was determined more then 2 days after admission
Reason For Censor N Late answer 53 Not Censored 9891
Table 1
| Overall | Not prone to death | Prone to death | p | Missing | |
|---|---|---|---|---|---|
| n | 9,891 | 8,918 | 973 | ||
| Age - Median (IQR) | 73.2 (62.9-82.9) | 72.7 (62.6-82.4) | 77.7 (66.3-88) | <0.001 | 0 |
| Male - N (%) | 5,213 (53) | 4,754 (53) | 459 (47) | <0.001 | 0 |
| BMI - Median (IQR) | 26 (23.1-29.7) | 26.1 (23.3-29.9) | 24.2 (21-27.3) | <0.001 | 45.9 |
| DM - N (%) | 2,818 (28) | 2,584 (29) | 234 (24) | 0.001 | 0 |
| Dyslipidemia - N (%) | 1,788 (18) | 1,671 (19) | 117 (12) | <0.001 | 0 |
| IHD - N (%) | 2,357 (24) | 2,158 (24) | 199 (20) | 0.01 | 0 |
| CHF - N (%) | 1,160 (12) | 1,059 (12) | 101 (10) | 0.186 | 0 |
| Stroke - N (%) | 2,138 (22) | 1,902 (21) | 236 (24) | 0.039 | 0 |
| Dementia - N (%) | 551 (6) | 424 (5) | 127 (13) | <0.001 | 0 |
| COPD - N (%) | 822 (8) | 750 (8) | 72 (7.4) | 0.306 | 0 |
| Solid Malignancy - N (%) | 1,680 (17) | 1,185 (13) | 495 (51) | <0.001 | 0 |
| Hematologic Malignancy - N (%) | 335 (3) | 307 (3) | 28 (2.9) | 0.406 | 0 |
| Chronic Meds AntiHypertensive - N (%) | 5,175 (52) | 4,794 (54) | 381 (39) | <0.001 | 0 |
| Chronic Meds Antiagregants - N (%) | 4,271 (43) | 3,982 (45) | 289 (30) | <0.001 | 0 |
| Chronic Meds Antiepileptic - N (%) | 1,191 (12) | 1,032 (12) | 159 (16) | <0.001 | 0 |
| Chronic Meds LipidLowering - N (%) | 4,421 (45) | 4,191 (47) | 230 (24) | <0.001 | 0 |
| Chronic Meds Diuretics - N (%) | 2,451 (25) | 2,221 (25) | 230 (24) | 0.407 | 0 |
| Chronic Meds antiCoagulant - N (%) | 750 (8) | 640 (7) | 110 (11) | <0.001 | 0 |
| HGB - Median (IQR) | 11.93 (10.38-13.29) | 12.03 (10.55-13.38) | 10.55 (9.15-12.1) | <0.001 | 5.7 |
| eGFR MDRD - Median (IQR) | 76.5 (51.7-101.6) | 77 (52.8-101.3) | 71.1 (40.6-106.8) | 0.005 | 3.9 |
Kaplan-Meier
Univariate analysis
| exp(coef) [confint] | p | |
|---|---|---|
| prone.to.death | 7.58 [7.02, 8.19] | <0.001 |
| Age | 1.04 [1.04, 1.05] | <0.001 |
| Male | 0.99 [0.93, 1.05] | 0.796 |
| BMI | 0.96 [0.95, 0.97] | <0.001 |
| DM | 1.26 [1.18, 1.35] | <0.001 |
| Dyslipidemia | 0.93 [0.86, 1.01] | 0.069 |
| IHD | 1.34 [1.26, 1.44] | <0.001 |
| COPD | 1.60 [1.46, 1.76] | <0.001 |
| SolidMalignancy | 2.51 [2.34, 2.69] | <0.001 |
| Dementia | 2.77 [2.51, 3.06] | <0.001 |
| HematologicMalignancy | 1.35 [1.16, 1.56] | <0.001 |
| ChronicMeds_AntiHypertensive | 1.04 [0.98, 1.11] | 0.195 |
| ChronicMeds_Antiagregants | 0.95 [0.90, 1.01] | 0.133 |
| ChronicMeds_Antiepileptic | 1.27 [1.16, 1.38] | <0.001 |
| ChronicMeds_LipidLowering | 0.74 [0.69, 0.78] | <0.001 |
| ChronicMeds_Diuretics | 1.87 [1.76, 2.00] | <0.001 |
| ChronicMeds_antiCoagulant | 1.64 [1.48, 1.81] | <0.001 |
| HGB | 0.80 [0.79, 0.81] | <0.001 |
| eGFR_MDRD | 0.99 [0.99, 0.99] | <0.001 |
Multivariate Model
| exp(coef) [confint] | p | |
|---|---|---|
| prone.to.death | 3.25 [2.85, 3.71] | <0.001 |
| Age | 1.03 [1.02, 1.03] | <0.001 |
| Male | 1.17 [1.08, 1.28] | <0.001 |
| BMI | 0.97 [0.96, 0.98] | <0.001 |
| DM | 1.10 [1.01, 1.21] | 0.031 |
| Dyslipidemia | 0.89 [0.80, 0.99] | 0.026 |
| IHD | 0.97 [0.88, 1.07] | 0.506 |
| CHF | 1.57 [1.41, 1.75] | <0.001 |
| Stroke | 0.98 [0.89, 1.08] | 0.714 |
| Dementia | 1.47 [1.26, 1.71] | <0.001 |
| COPD | 1.41 [1.24, 1.60] | <0.001 |
| SolidMalignancy | 1.78 [1.62, 1.96] | <0.001 |
| HematologicMalignancy | 1.29 [1.08, 1.55] | 0.006 |
| HGB | 0.88 [0.87, 0.90] | <0.001 |
| as.factor(eGFR_MDRD < 30)TRUE | 1.43 [1.27, 1.62] | <0.001 |
Propensity Matching
Population was matched using 1:1 nearest neighbor technique. The following variables were used to perform the Matching: Age, Male, BMI,DM,Dyslipidemia,IHD,CHF,Stroke,Dementia,COPD,Solid Malignancy, Hematologic Malignancy,HGB
Final matched cohort consisted of 710, 355 patients in each group
Univariate analysis
| exp(coef) [confint] | p | |
|---|---|---|
| prone.to.death | 5.26 [2.89, 9.56] | <0.001 |
Quality of match
Survival in matched poopulation
